argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) P/E ratio
As of 5 November 2026, argenex SE (ARGX) trades at a P/E ratio of 29.8×. Over the past ten years it has ranged from 0.0× (December 2024) to 48.8× (February 2025); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 40.0× | (10.57%) |
| FY2024 | 44.7× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 31.8× | (5.07%) |
| Jun 2026 | 33.5× | 10.73% |
| Mar 2026 | 30.2× | (24.38%) |
| Dec 2025 | 40.0× | 36.56% |
| 25 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| MRNA Moderna, Inc. compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| REGN Regeneron Pharmaceuticals, Inc. compare | 19.2× |
| ARGX argenex SE | 29.8× |
| GMAB Genmab A/S Sponsored ADR compare | 41.7× |
| RPRX Royalty Pharma PLC compare | 44.8× |
| INCY Incyte Corporation compare | 56.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 65.9× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement